Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hologic announces public offering of convertible senior notes
Hologic expects to grant to the underwriters an option to purchase up to an additional $195 million aggregate principal amount of notes to cover over-allotments. Goldman, Sachs &
Hologic expects to grant to the underwriters an option to purchase up to an additional $195 million aggregate principal amount of notes to cover over-allotments. Goldman, Sachs &
Under the terms of the agreement, ThioPharma will receive an upfront payment and milestone payments upon achievement of certain development and regulatory events. Cenomed has also agreed to
Enrollment was completed approximately one month ahead of schedule, with results from the study expected to be available by the third quarter of 2008. This study will evaluate
PS433540 is a dual-acting angiotensin and endothelin receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. Data demonstrated that PS433540 produced statistically
In this test, both uncoated and Cerashield coated tube segments were exposed to daily challenges of one million colony forming units per ml of Pseudomonas aeruginosa in nutrient
Accordingly, Ipsen and Erasmus Research Institute for Neuroendocrinology research teams will meet regularly to identify new therapeutic opportunities leading to novel pharmaceutical compounds, or the identification of novel
GeoPharma said that the only ovarian cancer diagnostic test is the CA-125 blood test that is approved by the FDA to monitor progression of the disease. For best
The candidate, AVI-4658, uses Avi’s exon skipping pre-RNA interference technology (ESPRIT) to potentially benefit Duchenne muscular dystrophy (DMD) patients who have mutations in exon 51 of the dystrophin
Neoprobe holds the exclusive rights to Lymphoseek under license from University of California, San Diego for use in diagnostic applications such as lymphatic mapping as well as in
The clinical trial is expected to enroll up to 50 patients in up to 12 centers throughout the US. The Phase II clinical trial is a three-sequence, open-label,